NasdaqGS - Delayed Quote
USD
Krystal Biotech, Inc. (KRYS)
266.04
+3.78
(+1.44%)
At close: May 1 at 4:00:00 PM EDT
266.10
+0.06
(+0.02%)
After hours: May 1 at 7:40:03 PM EDT
Trade KRYS on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for KRYS
- Previous Close
262.26 - Open
263.13 - Bid 185.64 x 200
- Ask 265.95 x 100
- Day's Range
256.92 - 266.38 - 52 Week Range
122.80 - 298.30 - Volume
252,090 - Avg. Volume
282,126 - Market Cap (intraday)
7.831B - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
38.89 - EPS (TTM)
6.84 - Earnings Date May 4, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
315.00
Recent News: KRYS
View More
Performance Overview: KRYS
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
KRYS
7.91%
S&P 500 (^GSPC)
5.62%
1-Year Return
KRYS
60.56%
S&P 500 (^GSPC)
29.01%
3-Year Return
KRYS
208.67%
S&P 500 (^GSPC)
73.47%
5-Year Return
KRYS
234.89%
S&P 500 (^GSPC)
72.92%
Earnings Trends: KRYS
View MoreAnalyst Insights: KRYS
View MoreStatistics: KRYS
View MoreValuation Measures
As of 5/1/2026
-
Market Cap
7.83B
-
Enterprise Value
7.01B
-
Trailing P/E
38.89
-
Forward P/E
46.08
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
20.48
-
Price/Book (mrq)
6.42
-
Enterprise Value/Revenue
18.02
-
Enterprise Value/EBITDA
41.78
Financial Highlights
Profitability and Income Statement
-
Profit Margin
52.64%
-
Return on Assets (ttm)
8.44%
-
Return on Equity (ttm)
18.91%
-
Revenue (ttm)
389.13M
-
Net Income Avi to Common (ttm)
204.83M
-
Diluted EPS (ttm)
6.84
Balance Sheet and Cash Flow
-
Total Cash (mrq)
827.79M
-
Total Debt/Equity (mrq)
0.77%
-
Levered Free Cash Flow (ttm)
93.93M
Compare To: KRYS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: KRYS
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: KRYS
View More-
Lowering target price to $296.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $296.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target -
Raising target price to $300.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $300.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target -
Raising target price to $297.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $297.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target -
Raising target price to $290.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $290.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target
